Kooperativer Bibliotheksverbund

In: Blood, American Society of Hematology, Vol. 140, No. Supplement 1 ( 2022-11-15), p. 11026-11028

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2022-159615

Language: English

Publisher: American Society of Hematology

Publication Date: 2022

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Applied Psychology, Wiley, Vol. 36, No. 2 ( 1987-04), p. 185-202

Type of Medium: Online Resource

ISSN: 0269-994X , 1464-0597

URL: Issue

URL: Article

DOI: 10.1111/apps.1987.36.issue-2

DOI: 10.1111/j.1464-0597.1987.tb00384.x

Language: English

Publisher: Wiley

Publication Date: 1987

detail.hit.zdb_id: 1483073-5

SSG: 5,2

In: Blood, American Society of Hematology, Vol. 138, No. Supplement 1 ( 2021-11-05), p. 2328-2328

Abstract: Introduction: Venetoclax (VEN) is a BCL-2 inhibitor FDA approved in combination with azacitidine (AZA), decitabine (DEC), or low-dose cytarabine (LDAC) for newly diagnosed (ND) acute myeloid leukemia (AML) in adults aged ≥75 or those with comorbidities precluding intensive chemotherapy. We explored real-world practices and clinical outcomes of patients (pts) treated with VEN-based vs. non-VEN-based regimens in the AML Real world evidenCe (ARC) Initiative. Methods: This multicenter chart review study includes adult pts with ND AML treated with VEN (VEN cohort) after 11 April 2016 matched to pts with non-VEN-based regimens (control cohort) after 15 May 2015 from 10 academic sites in the US and 4 in Israel. Pts were randomly selected and matched on age ( & lt;60; 60-74; ≥75) and ELN risk. Interim descriptive results (data cut: 17 May 2021) are presented; data collection is ongoing with a targeted sample of ≥500 matched pts. Response to therapy, as reported by physicians in the patient chart, hematopoietic cell transplantation (HCT) rate, and Kaplan-Meier (KM) estimates of overall survival (OS), event-free survival (EFS), and duration of response (DOR) were analyzed. Subgroups of pts aged & lt;75 and with adverse ELN risk were analyzed separately. Results: Select results are shown in Table 1. 133 VEN and 133 control ND AML pts were included. Median age was 73 years (Range: 34-89) in the VEN cohort and 71 years (Range: 40-89) in the control cohort; 60.9% of matched pts were & lt;75 ( & lt;75 subgroup; 81 VEN and 81 control). In both cohorts, 64.7% of pts had adverse ELN risk. VEN pts received VEN+AZA (106 pts, 79.7%), VEN+DEC (24 pts, 18.0%), or VEN+LDAC (3 pts, 2.3%). In the control cohort, 37.6% of pts received low-intensity regimens (largely DEC [19.5%] and AZA [14.3%] ) and 62.4% received high-intensity regimens (e.g., cytarabine+daunorubicin [27.1%] and CPX-351 [15.8%] ), with a higher proportion of pts on high-intensity regimens in the & lt;75 subgroup (85.2%) and a lower proportion in the adverse-risk subgroup (54.7%). IDH1/IDH2 mutations were present in 16.5% and 15.8% of pts in the VEN and control cohorts, respectively, and NPM1 mutations were present in 11.4% and 11.8% of pts. Across subgroups, TP53 mutation was present in higher proportions of VEN pts compared to control. The mean duration of follow-up was 9.2 months in the VEN cohort and 14.6 months in the control cohort and the mean duration of treatment was 6.9 months and 4.3 months. Composite complete remission (CCR: CR+CRi) rate was 60.4% in the VEN cohort and 50.0% in the control cohort and rate of MLFS was 7.2% and 3.4%, respectively; among the pts who achieved a response (CR, CRi, CRh, or MLFS; 81 VEN and 68 control pts), median time to best response was 1.7 months and 1.3 months, respectively. The 1-year KM DOR for patients who achieved CCR was 57.7% in the VEN cohort and 53.1% in the control cohort. After initial therapy, 5.3% of pts in the VEN cohort and 15.0% of pts in the control cohort were referred to HCT. The 1-year KM OS was 62.6% in the VEN cohort and 49.8% in the control cohort and the 1-year KM EFS was 41.4% and 31.5%. In the & lt;75 subgroup (81 VEN and 81 control pts), outcomes were similar between cohorts, despite a higher proportion of pts with comorbidities in the VEN cohort (87.7%) than the control cohort (77.8%); rates of CCR were 61.2% in the VEN cohort and 57.1% in the control cohort; after initial chosen therapy, 7.4% and 22.2% of pts were referred to HCT in the VEN and control cohort, respectively. The 1-year KM OS was 55.4% in the VEN cohort and 55.5% in the control cohort, and the 1-year KM EFS was 38.4% and 38.1%. In the adverse-risk subgroup, rates of CCR were 50.7% in the VEN cohort and 37.8% in the control cohort; after initial chosen therapy, 4.7% and 10.5% of pts were referred to HCT in the VEN and control cohort, respectively. The 1-year KM OS was 51.1% in the VEN cohort and 39.8% in the control cohort and the 1-year KM EFS was 28.4% and 27.2%. Conclusions: The current analyses support real-world treatment effectiveness of VEN combinations and are consistent with data reported from clinical trials, despite the relatively short follow-up at the time of interim analyses. The outcomes, including OS at 1 year, for VEN combinations in ND AML pts appear similar to matched control pts, including the subgroup of pts & lt;75 who largely received high-intensity regimens, and a lower proportion had comorbidities. Further analyses of matched pts are ongoing. Figure 1 Figure 1. Disclosures Garcia: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; Pfizer: Research Funding; Prelude: Research Funding; AstraZeneca: Research Funding. Wolach: Neopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Research Funding. Vachhani: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Blueprint Medicines: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees. Talati: Jazz: Speakers Bureau; BMS: Honoraria; Pfizer: Honoraria; AbbVie: Honoraria; Astellas: Speakers Bureau. Pollyea: Karyopharm: Consultancy; Syndax: Consultancy; Amgen: Consultancy; AbbVie: Consultancy, Research Funding; Novartis: Consultancy; Genentech: Consultancy; Janssen: Consultancy; Celgene/BMS: Consultancy; Pfizer: Consultancy; Takeda: Consultancy; Daiichi Sankyo: Consultancy; Agios: Consultancy; Glycomimetics: Other. Lai: Jazz Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Speakers Bureau; Macrogenics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz Pharma: Speakers Bureau; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees. Moshe: Astellas: Membership on an entity's Board of Directors or advisory committees, Other: Lectures; AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Lectures; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Lectures. Abedin: Astellas Pharma Inc.: Research Funding; Amgen: Honoraria; Pfizer: Research Funding; Actinium: Research Funding; AltruBio: Research Funding; Agios: Honoraria; Helsinn: Research Funding. Lavie: AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Fees for lectures; BMS: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Other: Fees for lectures; Roche: Other: Fees for lectures; Novartis: Other: Fees for lectures. Zuckerman: AbbVie: Honoraria; Orgenesis Inc.: Honoraria; BioSight Ltd: Honoraria; Janssen: Honoraria; Novartis: Honoraria; Gilead Sciences: Honoraria, Speakers Bureau; Cellect Biotechnology: Honoraria. Xavier: ADC Therapeutics: Speakers Bureau; Epizyme: Speakers Bureau; Celgene/BMS: Speakers Bureau; Seattle Genetics: Speakers Bureau; Morphosys/Incyte: Speakers Bureau; Beigene: Speakers Bureau; Acrotec: Consultancy; Genentech: Honoraria; Kite/Gilead: Honoraria; Jansen/Pharmacyclics: Honoraria; AstraZeneca: Honoraria, Speakers Bureau; Verastem: Honoraria; AbbVie: Consultancy, Speakers Bureau. Lee: AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Innate: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pin Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees. Bui: Abbvie: Current Employment, Other: May hold equity. Svensson: AbbVie: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company. Burne: Analysis Group Inc: Current Employment, Other: Analysis Group Inc received consulting funds from AbbVie. Kye: AbbVie: Current Employment, Other: May hold equity. Maitland: Analysis Group Inc: Current Employment, Other: Analysis Group Inc received consulting funds from AbbVie. Ma: Genentech, Inc.: Current Employment, Other: May hold equity. Montez: Genentech, Inc: Current Employment, Other: May hold equity. Grunspan: AbbVie: Current Employment, Other: May hold equity. Goldberg: Aptose: Consultancy, Research Funding; Arog: Research Funding; Pfizer: Research Funding; Prelude Therapeutics: Research Funding; Aprea: Research Funding; Celularity: Research Funding; DAVA Oncology: Honoraria; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2021-151285

Language: English

Publisher: American Society of Hematology

Publication Date: 2021

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 138, No. Supplement 1 ( 2021-11-05), p. 1271-1271

Abstract: Introduction: Venetoclax (VEN) is a novel BCL-2 inhibitor indicated in the US for treatment of newly-diagnosed (ND) acute myeloid leukemia (AML) in adults ≥75 years or with comorbidities precluding use of intensive chemotherapy, in combination with azacitidine (AZA), decitabine (DEC), or low-dose cytarabine (LDAC). Despite widespread clinical use of VEN combinations in ND AML, real-world practice patterns are largely unknown. We set out to explore real-world outcomes and treatment paradigms in ND AML patients treated with VEN-based regimens. Methods: The AML Real world evidenCe (ARC) Initiative is a multicenter chart review study of adult pts with ND AML treated with VEN-based regimens and matched control pts (by age and ELN risk) from different academic sites in the US (10 sites) and Israel (4 sites), assessing real-world outcomes as well as VEN treatment practices. Interim descriptive results with data cutoff of 17 May 2021 are presented; data collection is ongoing, with a targeted sample size of over 250 VEN pts and further global expansion planned. Descriptive results are presented here on VEN-related treatment practices overall, and separately in the US and Israel. Results: At data cutoff, 133 VEN ND AML pts were included. The majority of pts were treated at US sites (102 pts, 76.7%). Regimens administered were VEN+AZA (106 pts, 79.7%), VEN+DEC (24 pts, 18.0%), and VEN+LDAC (3 pts, 2.3%). In Israel, all pts were treated with VEN+AZA (31 pts, 100.0%). Median age was 73.2 years, and the majority of pts (64.7%) had adverse ELN risk. Common genetic mutations observed included TP53 (30 pts, 22.7%), RUNX1 (21 pts,15.9%), IDH1/IDH2 (22 pts, 16.5%), NPM1 (15 pts, 11.4%), and FLT3 ITD (12 pts, 9.1%). Mean [median] duration of follow-up was 9.2 months [7.1] and duration of VEN-based treatment was 6.9 months [4.1]. 27.8% of pts had discontinued VEN. Among those who discontinued (37 pts), reasons for discontinuation included intolerance (13/37 pts, 35.1%), relapse (8/37 pts, 21.6%), and insufficient response (7/37 pts, 18.9%; results not shown). Unplanned dose interruptions during therapy were observed for 40 pts (30.1%) with common reasons including severe febrile neutropenia (13/40 pts, 32.5%), neutropenia (severe: 10/40 pts, 25.0%; non-severe: 5/40 pts, 12.5%), and patient request (6/40 pts, 15.0%). Venetoclax ramp-up was performed for 74.4% of pts overall and was more common in Israel (29 pts, 93.5%) than US sites (70 pts 68.6%). Among pts with venetoclax ramp-up performed, the majority received initial VEN treatment in the inpatient setting (US: 47/70 pts, 67.1%; Israel: 25/29 pts 86.2%), median starting and ending doses were 100mg and 400mg respectively, and median ramp-up duration was 3 days; which was similar in the US and Israel. Antifungal use during the first cycle, either prophylactically or in response to an infection, was observed in two-thirds of pts (88 pts, 66.2%) and was more common in the US (72 pts, 70.6%). Among pts with prophylactic antifungal use of a strong CYP3A4 inhibitor (33 pts, 24.8%), 42.4% of pts did not ramp-up and started and maintained a venetoclax dose of 100mg. At data cutoff, 120 pts had laboratory testing and bone marrow assessment results available in the full sample. Of these pts, timing of first bone marrow biopsy assessments varied, with 44.5% of pts having an assessment in their first cycle of venetoclax and 11.8% of pts having an assessment after the first two cycles. In Israel, a higher proportion of pts had a bone marrow assessment during their first cycle of venetoclax (18 pts, 58.1%). Out of those with response assessed (111 pts, 90.2%), 65.8% of pts achieved a response of CR, CRh, or CRi (US: 54/86 pts, 62.8%; Israel: 19/25 pts, 76.0%). Conclusions: The ongoing ARC Initiative provides insights on real-world treatment practices and management of ND AML pts treated with VEN-based regimens from academic sites. The ramp-up and dosing patterns appear consistent with label, with some variation. Delay in timing of bone marrow assessments may affect the assessment of time to response and post-response management in the real-world. Additional data collection in the ARC Initiative will provide more robust and valuable insights into VEN-based treatment practices and management in the real world. Figure 1 Figure 1. Disclosures Vachhani: Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Blueprint Medicines: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees. Wolach: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Neopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Research Funding. Garcia: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; Pfizer: Research Funding; Prelude: Research Funding; AstraZeneca: Research Funding. Talati: Pfizer: Honoraria; AbbVie: Honoraria; BMS: Honoraria; Jazz: Speakers Bureau; Astellas: Speakers Bureau. Pollyea: Takeda: Consultancy; Daiichi Sankyo: Consultancy; Syndax: Consultancy; Karyopharm: Consultancy; Novartis: Consultancy; AbbVie: Consultancy, Research Funding; Agios: Consultancy; Glycomimetics: Other; Amgen: Consultancy; Janssen: Consultancy; Genentech: Consultancy; Celgene/BMS: Consultancy; Pfizer: Consultancy. Lai: Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Macrogenics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Speakers Bureau; Jazz Pharma: Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees. Moshe: Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Lectures; Astellas: Membership on an entity's Board of Directors or advisory committees, Other: Lectures; AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Lectures. Abedin: Agios: Honoraria; Actinium: Research Funding; AltruBio: Research Funding; Helsinn: Research Funding; Pfizer: Research Funding; Amgen: Honoraria; Astellas Pharma Inc.: Research Funding. Lavie: AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Fees for lectures; BMS: Membership on an entity's Board of Directors or advisory committees; Takeda: Other: Fees for lectures; Roche: Other: Fees for lectures; Novartis: Other: Fees for lectures; Takeda: Consultancy. Zuckerman: Cellect Biotechnology: Honoraria; Gilead Sciences: Honoraria, Speakers Bureau; Novartis: Honoraria; Janssen: Honoraria; BioSight Ltd: Honoraria; Orgenesis Inc.: Honoraria; AbbVie: Honoraria. Xavier: AbbVie: Consultancy, Speakers Bureau; Morphosys/Incyte: Speakers Bureau; Jansen/Pharmacyclics: Honoraria; ADC Therapeutics: Speakers Bureau; Epizyme: Speakers Bureau; Genentech: Honoraria; Kite/Gilead: Honoraria; Beigene: Speakers Bureau; Acrotec: Consultancy; Seattle Genetics: Speakers Bureau; AstraZeneca: Honoraria, Speakers Bureau; Verastem: Honoraria; Celgene/BMS: Speakers Bureau. Lee: Pin Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Innate: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees. Bui: Abbvie: Current Employment, Other: May hold equity. Svensson: AbbVie: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company. Kye: AbbVie: Current Employment, Other: May hold equity. Burne: Analysis Group Inc: Current Employment, Other: Analysis Group Inc received consulting funds from AbbVie. Maitland: Analysis Group Inc: Current Employment, Other: Analysis Group Inc received consulting funds from AbbVie. Ma: Genentech, Inc.: Current Employment, Other: May hold equity. Montez: Genentech, Inc: Current Employment, Other: May hold equity. Grunspan: AbbVie: Current Employment, Other: May hold equity. Goldberg: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Arog: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Research Funding; Aptose: Consultancy, Research Funding; Aprea: Research Funding; DAVA Oncology: Honoraria; Celularity: Research Funding; Prelude Therapeutics: Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2021-151586

Language: English

Publisher: American Society of Hematology

Publication Date: 2021

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Language Testing, SAGE Publications, Vol. 5, No. 1 ( 1988-06), p. 100-114

Abstract: The major aim of the present research is twofold: (a) to compare students' atti tudes towards oral versus written English language test; and (b) to examine the nature of the relationship between students' affective dispositions toward lan guage tests and level of test performance. The study is based on a sample of 170 students at Haifa University enrolled in the advanced reading course of English as a foreign language. Students responded to an examinee feedback inventory specifically designed to gauge examinees' perceptions of key variables related to mode of test presentation (oral vs. written examinations). In addition, back ground information was collected on students' gender, sociolinguistic back ground, father's education, the university psychometric entrance examination (including the English proficiency test score), and average grade in department of study. On the whole, students preferred written over oral tests and rated the former more favourably along a variety of dimensions. Written tests were per ceived to be more pleasant, valuable, fair, less anxiety evoking and more reflec tive of students' comprehension of the English text than oral tests. Oral tests, on the other hand, were viewed to be more interesting to take than written tests. No meaningful relationship, however, was observed between students' atti tudes and test performance.

Type of Medium: Online Resource

ISSN: 0265-5322 , 1477-0946

URL: Article

DOI: 10.1177/026553228800500107

Language: English

Publisher: SAGE Publications

Publication Date: 1988

detail.hit.zdb_id: 999075-6

detail.hit.zdb_id: 2023709-1

SSG: 7,11

In: Contemporary Educational Psychology, Elsevier BV, Vol. 17, No. 3 ( 1992-7), p. 224-243

Type of Medium: Online Resource

ISSN: 0361-476X

URL: Article

DOI: 10.1016/0361-476X(92)90062-4

Language: English

Publisher: Elsevier BV

Publication Date: 1992

detail.hit.zdb_id: 1462923-9

SSG: 5,2

In: Journal of Environmental Psychology, Elsevier BV, Vol. 8, No. 3 ( 1988-9), p. 191-208

Type of Medium: Online Resource

ISSN: 0272-4944

URL: Article

DOI: 10.1016/S0272-4944(88)80009-4

Language: English

Publisher: Elsevier BV

Publication Date: 1988

detail.hit.zdb_id: 1469212-0

detail.hit.zdb_id: 225879-1

SSG: 5,2

In: The Journal of Educational Research, Informa UK Limited, Vol. 80, No. 6 ( 1987-07), p. 352-358

Type of Medium: Online Resource

ISSN: 0022-0671 , 1940-0675

URL: Article

DOI: 10.1080/00220671.1987.10885782

Language: English

Publisher: Informa UK Limited

Publication Date: 1987

detail.hit.zdb_id: 219181-7

detail.hit.zdb_id: 2066581-7

SSG: 5,3

In: The Journal of Social Psychology, Informa UK Limited, Vol. 128, No. 3 ( 1988-06), p. 333-343

Type of Medium: Online Resource

ISSN: 0022-4545 , 1940-1183

URL: Article

DOI: 10.1080/00224545.1988.9713750

Language: English

Publisher: Informa UK Limited

Publication Date: 1988

detail.hit.zdb_id: 2066653-6

detail.hit.zdb_id: 3135-5

SSG: 5,2

In: Gifted Education International, SAGE Publications, Vol. 33, No. 2 ( 2017-05), p. 163-182

Abstract: This article aims at shedding light on the emotional intelligence (EI) of gifted and high ability students. We begin by presenting a brief overview of EI theory and research and its relevance to gifted education. We then present theoretical considerations bearing on the nature of the relationship between cognitive and EI. This is followed by a survey of correlational and individual difference research bearing on the EI-high ability nexus. We then move on to present a number of general guidelines for the development of an EI training program designed to foster emotional and social competencies in gifted students. We conclude by offering some broad generalizations about EI in gifted students and point out the areas of needed future research.

Type of Medium: Online Resource

ISSN: 0261-4294 , 2047-9077

URL: Article

DOI: 10.1177/0261429417708879

Language: English

Publisher: SAGE Publications

Publication Date: 2017

detail.hit.zdb_id: 2554331-3

SSG: 5,3